electroCore, Inc. (NASDAQ:ECOR – Get Free Report) Director Thomas J. Errico purchased 6,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $8.10 per share, for a total transaction of $48,600.00. Following the acquisition, the director now directly owns 256,401 shares in the company, valued at approximately $2,076,848.10. The trade was a 2.40 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
electroCore Stock Performance
Shares of ECOR opened at $8.26 on Tuesday. electroCore, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $19.49. The firm has a market cap of $54.98 million, a price-to-earnings ratio of -4.51 and a beta of 0.24. The firm has a 50 day moving average price of $15.64 and a 200-day moving average price of $12.37.
Institutional Trading of electroCore
Several hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of electroCore by 31,250.0% during the fourth quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock valued at $61,000 after buying an additional 3,750 shares during the last quarter. DnB Asset Management AS bought a new position in electroCore during the 4th quarter worth approximately $180,000. HighTower Advisors LLC purchased a new position in electroCore in the 3rd quarter worth approximately $255,000. NewEdge Advisors LLC bought a new stake in electroCore in the fourth quarter valued at approximately $274,000. Finally, Jane Street Group LLC purchased a new stake in shares of electroCore during the fourth quarter valued at approximately $278,000. 26.74% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on ECOR
electroCore Company Profile
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Recommended Stories
- Five stocks we like better than electroCore
- How to Choose Top Rated Stocks
- Can TikTok Stock Picks Really Make You Rich?
- What is diluted earnings per share (Diluted EPS)?
- The “Quality” Rotation: Back to Basics Investing
- How to Calculate Options Profits
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.